Akèy › Kansè nan tete › Massachusetts
Etid klinik pou Kansè nan tete nan Massachusetts
117 etid pou Kansè nan tete ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
- Boston111 etid
- Somerville8 etid
- Worcester6 etid
- Quincy6 etid
- Brockton5 etid
- Lynn5 etid
- Lawrence4 etid
- Newton4 etid
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07701941Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 70 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT04305834Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571IKS014 in Advanced Solid Tumors That Express HER2
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05872295A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Massachusetts General Hospital, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05646862A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037), Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Brigham Cancer Center Foxborough, Foxborough
- Dana-Farber Cancer Institute Merrimack Valley, Methuen
- ak 2 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Massachusetts General Hospital, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- University of Massachusetts Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 21, 2026 · NCT07524855A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05894239ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Lahey Hospital & Medical Center, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Massachusetts General Hospital, Boston
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- ak 8 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT04899908Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05386108A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Tufts Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Beverly Hospital, Beverly
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- ak 12 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06488378A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 a 100 · Tout sèks · Mizajou Aug 27, 2026 · NCT06726148Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.